StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 100.0%, against 100.0% the year before. The highest annual figure on record is 100.0% in fiscal 2024.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025100.0%+0.0
FY2024Dec 31, 2024100.0%+97.6
FY2023Dec 31, 20232.4%−88.4
FY2022Dec 31, 202290.8%−3.2
FY2021Dec 31, 202193.9%−2.3
FY2020Dec 31, 202096.2%+71.2
FY2019Dec 31, 201925.0%−53.5
FY2018Dec 31, 201878.5%−11.1
FY2017Dec 31, 201789.6%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2023Jun 30, 202369.1%+39.8
Q2 FY2022Jun 30, 202274.8%–
Q2 FY2021Jun 30, 2021-5.2%–
Q2 FY2020Jun 30, 2020-100.9%–
Q2 FY2019Jun 30, 201929.3%–

More Cellectis figures

See a number that looks wrong?